Le Lézard
Classified in: Health
Subjects: POL, AVO, CFG, MAT

Canada to have the world's best tobacco plain packaging requirements


Canadian Cancer Society praises regulations released today

OTTAWA, June 22, 2018 /CNW/ - The Canadian Cancer Society is commending the new national regulations for tobacco plain packaging as the most effective in the world. The regulations were released today by Minister of Health Ginette Petitpas Taylor.

"We strongly support the regulations released today as they are essential for protecting Canadian kids from tobacco industry marketing," says Rob Cunningham, Senior Policy Analyst, Canadian Cancer Society. "Tobacco is addictive and deadly and should not be sold in packages made to be more attractive. Tobacco packaging should not function as mini-billboards promoting tobacco use."

"Canada's plain packaging regulations will be the best and most comprehensive in the world," adds Cunningham. "We appreciate the global leadership being demonstrated by Minister Petitpas Taylor in bringing these regulations forward."

The Canadian Cancer Society has been advocating for tobacco plain packaging regulations since the 1990s. In 1994, the House of Commons Standing Committee on Health recommended plain packaging. Today's announcement represents an enormous public health policy victory.

The regulations include the following provisions:

To date, eight countries have finalized requirements for plain packaging: Australia, New Zealand, United Kingdom, France, Ireland, Norway, Hungary and Slovenia.  Many more countries are also developing requirements. Plain packaging is recommended by the World Health Organization as an effective tobacco control measure

The regulations released today are subject to a 75-day consultation period. Once the regulations are finalized, tobacco manufacturers will be allowed a transition period to change their packages. Plain packaging is expected to be on store shelves at some point in 2019.

Tobacco use is the leading preventable cause of disease and death in Canada, killing more than 45,000 Canadians annually. It is responsible for about 30% of all cancer deaths and for $6.5 billion in annual health care costs.

Canada-wide, smokers can call the number on cigarette packages 1-866-366-3667 to receive proven and personalized support to quit smoking. The Canadian Cancer Society operates the quitline in Saskatchewan, Manitoba, Ontario, New Brunswick, PEI, and the Yukon through Smokers' Helpline and the ligne j'ARRÊTE in Quebec. 

About the Canadian Cancer Society
The Canadian Cancer Society is a national community-based organization whose mission is the eradication of cancer and the enhancement of the quality of life of people living with cancer. When you want to know more about cancer, visit our website www.cancer.ca or call our toll-free, bilingual Cancer Information Service at 1 888 939-3333.

SOURCE Canadian Cancer Society (National Office)


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: